Sorrento TherapeuticsInc. (NASDAQ:SRNE) traded at $7.91 at close of the session on Tuesday, May 04, made a downturn move of -3.89% on its previous day’s price.
Looking at the stock we see that its previous close was $8.23 and the beta (5Y monthly) reads 2.36 with the day’s price range being $7.84 – 8.43. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, SRNE has a high of $19.39 and a low of $2.18. The company’s stock has gained about -1.25% over that past 30 days.
Sorrento TherapeuticsInc. has a market cap of $2.33 Billion and is expected to release its quarterly earnings report on May 11, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the SRNE stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0.38, with the EPS growth for the year raised at $1.67 for 2021 and $1.72 for next year. These figures represent -2.28% and 0.03% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $17.25 Million, with a low of $8.36 Million and a high of $22.2 Million. The median projection represents growth adding up to 123.4% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $1.1 Billion, or +2658.7% up from figures reported last year.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the SRNE stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Sorrento TherapeuticsInc. (SRNE) stock as a Hold, while 3 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the SRNE stock currently stands at 0, and the current price level is 1.62% off its SMA20 and -11.1% from its 50-day simple moving average. The RSI (14) is pointing at 45.5 while the volatility over the past week is 7.09% and drops to 6.92% over the past one month. The beta value is 2.36, while the average true range (ATR) is currently pointing at 0.56. The average price target for the stock over the next 12 months is $25, with the estimates having a low of $19 and a high of $30. These price ends are 140.2% and +279.27% off the current price level respectively, although investors could be excited at the prospect of a +228.7% if the SRNE share price touches on the median price of $26.
Let’s briefly compare Sorrento TherapeuticsInc. (SRNE) stock to its peers. We find that current price change of -3.89% and +242.42% over the past 12 months for SRNE competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price rise 1.7% in the last trading session and was +5.34% over the last one year. Another of its peers Amgen Inc (AMGN) has climbed 2.4% previous session, and was +6.23% up over the past year, while Gilead Sciences Inc (GILD) was also down -3.89% in the last session, while its price remained in the green at 242.42% over the same period. Sorrento TherapeuticsInc. has a P/E ratio of 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 20.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 0.27% and 0.7%, respectively, at close of the trading.
Coming back to Sorrento TherapeuticsInc. (NASDAQ:SRNE), we note that the average 3-month trading volume was 17.08 Million, while that of the preceding 10-day period stands at 6.83 Million. Current shares outstanding are 285.66 Million.
According to data from Thomson Reuters, insiders hold 11.22% of the company’s shares while institutions hold 28.24%. The data shows that short shares as of April 14, 2021, stood at 59.55 Million at a short ratio of 7.08. This represents a 20.85% short interest in shares outstanding on April 14, 2021. Shares short rose in April from the previous month at 56.07 Million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +15.9% up in year-to-date price movement.